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5  years of diagnosis of glioma. Serial neuroimaging was 
undertaken in 88 patients. In 66 (75%), the lesion on the 
scan was stable or had improved at follow-up. High-grade 
lesions were present in five patients and were strongly 
associated with tumours in the thalamus (p = 0.001). Five 
patients died during follow-up. The diagnosis of high-grade 
glioma had a HR of 99.7 (95% CI 11.1–898.9, p < 000.1) 
on multivariate Cox regression to evaluate predictive fac-
tors related to death. In our cohort of 100 patients with 
NF1, we have shown that tumours in the thalamus are more 
likely to be associated with radiological progression, high-
grade tumours, and surgical intervention. As a result of this 
finding, heightened surveillance with more frequent imag-
ing should be considered in thalamic involvement. We have 
also demonstrated that over 40% of patients underwent sur-
gery, and did so within 5 years of tumour diagnosis. Serial 
imaging should be undertaken for at the very least, 5 years 
from tumour detection.
Keywords Neurofibromatosis type 1 (NF1) · Brain 
tumour · Pilocytic astrocytoma · Epidemiology · 
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Background and aims
Type 1 Neurofibromatosis (NF1) is a common autosomal 
dominant condition, with a major impact on the nervous 
system, eye, bone, and skin. NF1 is a tumour suppressor 
disorder that is typified by benign nerve sheath tumours 
and a predisposition to malignancy. Lack of the NF1 gene 
product neurofibromin arising from gene mutation causes 
activation of the ras pathway and unrestrained cell growth 
[1, 2]. The natural history of NF1-associated tumours 
Abstract Type 1 Neurofibromatosis (NF1) is a common 
autosomal dominant condition, with a major impact on the 
nervous system, eye, bone, and skin, and a predisposition 
to malignancy. At present it is not possible to predict clini-
cally or on imaging, whether a brain tumour will remain 
indolent or undergo high-grade change. There are no con-
sensus guidelines on the follow-up of non-optic pathway 
glioma (non-OPG) tumours in NF1. One hundred patients 
from the National NF1 Service with generalised NF1 and 
a diagnosis of non-OPG glioma were followed up for a 
median time of 63  months after glioma detection. Forty-
two patients underwent surgical intervention. Ninety-
one percent (38) of those requiring surgery did so within 
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differs from the general population [3], and NF1 individu-
als require specialist assessment and management.
Low-grade brain gliomas are a well-recognized com-
plication of NF1 and they may remain indolent over many 
years; however, a small number of low-grade gliomas trans-
form into more aggressive tumour types [4]. At present it is 
not possible to predict clinically or on imaging, whether a 
tumour will remain indolent or undergo high-grade change. 
Another small subset of patients may present acutely with 
a high-grade brain tumour without ever having had a low-
grade glioma identified. A study by Guillamo et al. looked 
at brain gliomas in NF1 and identified that extra-optic loca-
tion, tumours diagnosed in adulthood, and symptoms at 
diagnosis are associated with a higher mortality [4].
Two decades ago it was common practice to treat these 
low-grade tumours aggressively, however, more recent 
epidemiological studies have demonstrated an association 
between radiotherapy and subsequent malignant transfor-
mation [3], endocrine sequelae, neurovascular, and cogni-
tive difficulties. The majority of non-optic pathway glioma 
in NF1 are indolent, low-grade pilocytic astrocytomas 
and become symptomatic only when there is mechanical 
obstruction, or less commonly when malignant changes 
occur [5].
At the current time there are no consistent guidelines for 
identifying or monitoring non-optic pathway gliomas (non-
OPG) in patients with NF1, and this reflects the paucity of 
information on natural progression of these tumours.
The aim of our study was to carry out a retrospective 
review of all patients who attended our national neurofi-
bromatosis centre between 2009 and 2014 and who had a 
non-OPG glioma. The goal was to characterise the clinical 
presentation, management, progression, and outcome in 
this cohort.
Methods
All patients attending the National NF1 Service from 2009 
to 2014 with generalised NF1 (diagnosis made by clinical 
criteria and genetic analysis where appropriate) and ever 
had a history of non-OPG glioma were included. Data 
were extracted from clinical records by two researchers 
(SB, CW). Brain glioma was diagnosed on histology and/
or suspected on neuroimaging by two neuroradiologists 
with extensive experience in NF1 (over 1000 patients in 
15 years) using criteria such as persistent lesional enhance-
ment and/or mass effect. The neuroradiologists compared 
follow-up imaging to previous imaging using linear meas-
urement and qualitative assessment. Patients with mosaic 
NF1 or with brain metastases were excluded from assess-
ment. Reason for imaging was determined as (1) sympto-
matic—if the scan was carried out for symptoms related to 
the anatomical location of the tumour (2) unrelated—if the 
MRI was undertaken by the referring institution for screen-
ing purposes (although this is not our practice) or for symp-
toms unrelated to anatomical location of the tumour.
Extended disability scores (EDSS) [6] were calculated 
using reported examination at each visit. Information col-
lected is outlined in supplementary table 1.
Data analysis was carried out using SPSS 22 [IBM 
SPSS Statistics for Macintosh, Version 22.0]. Parametric 
tests were carried out where the data were normally dis-
tributed, and non-parametric tests were used if the data 
were not normally distributed. Chi Square testing or Fish-
er’s exact testing was used to compare two the relation-
ship between two categorical variables. Survival analysis, 
and time to event analysis was carried out using univari-
ate and Cox multivariate survival analysis, with time 
variable being time from glioma diagnosis to the event 
in question (e.g. surgery, death) or censor date. Statistical 
significance was set at <0.05.
This study was approved as a clinical evaluation with 
study number 5099 by the Clinical Audit Group Committee 
at Guy’s and St. Thomas’ NHS Foundation Trust, London.
Results
One hundred patients from our cohort had generalised 
NF1 and a diagnosis of non-OPG glioma (47 males, 53 
females). Median age at glioma diagnosis was 16 years 
(range 2–62 years), and 57 patients were under the age 
of 18 years at diagnosis. Patients were followed up for a 
median time of 63 months (range 0–452 months) after a 
glioma was detected.
Neuroimaging was initially performed in 44/100 
patients with glioma-related symptoms, in 53/100 indi-
viduals for unrelated reasons, and the reason was not 
available in 3/100 (see supplementary table 2).
Fig. 1  Venn diagram of location of non-OPG (n = 100)
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Location of tumours can be seen in Fig.  1. Diagnosis 
was made on neuroimaging only in 58/100, and on histo-
logical analysis and neuroimaging in 42/100.
Surgical intervention
Forty-two of the 100 patients underwent surgical interven-
tion during follow-up; initial surgical intervention was total 
or subtotal resection of tumour in 29, biopsy only in 6, and 
shunt or ventriculostomy only in 7 individuals.
Twenty-four patients had surgery for relief of symptoms, 
ten patients had surgery because of concern regarding the 
radiological features of the tumour, and in eight cases the 
specific reason for surgery was not stated in the medical 
notes.
Ten patients went on to have further surgical interven-
tion at a later stage. Of the ten who had further surgery, five 
required debulking (initial surgery was debulking in three, 
initial surgery was shunt/ventriculostomy in two), three 
required shunt revision (initial surgery was ventriculos-
tomy/shunt for all three), one required a shunt (initial sur-
gery was a biopsy), and one required a shunt and Omaya 
reservoir insertion (initial surgery was a biopsy).
The requirement for surgical intervention was much 
higher in the cohort of patients who had a scan because of 
glioma-related symptoms at presentation (31 of 44; 71%), 
compared to those who had an MRI for screening or other 
reasons (11 of 56), p < 0.0001. Symptomatic reasons for 
surgical intervention included seizures, raised intracranial 
pressure, rapid increase in size of tumour, and hemiparesis.
Twenty-seven of 42 patients (64%) requiring surgical 
intervention did so within 2  months of presentation, and 
38/42 (91%) had surgery within 5 years of diagnosis of gli-
oma. Only four patients (9%) had surgery beyond 5 years, 
three because of radiological progression and one because 
of symptoms (see Fig. 2).
Multivariate Cox regression was performed looking at 
predictive factors for surgery. Significant variables were 
thalamic involvement [Hazard ratio (HR) 2.18, 95% CI 
1.01–4.6, p = 0.049], frontal involvement (HR 3.36, 95% 
CI 1.49–7.6, p = 0.004), and cerebellar involvement (HR 
4.44, 95% CI 2.0–9.8, p < 0.0001). Presence of a high-
grade glioma was also a significant risk factor for surgery 
(HR 3.46, 95% CI 1.33–9, p = 0.011). Age at diagnosis was 
not a significant variable (HR 0.975, 95% CI 0.94–1.004, 
p = 0.087).
Three patients required surgical intervention, radio-
therapy and chemotherapy, four had surgery and chemo-
therapy, and four had surgery and radiotherapy. None had 
chemotherapy alone. Of the 11 patients who received more 
than one treatment modality, eight patients had multimodal 
treatment initially, and three patients had additional treat-
ments added after progression.
Histology
Formal histology results were available on 32 patients: 23 
pilocytic astrocytoma, 5 glioblastoma multiforme, 3 gangli-
oglioma, and 1 pilomyxoid glioma (grade 2). One of our 
patients underwent molecular analysis and had a BRAF 
V600E mutation.
High-grade lesions were present in five patients and 
were strongly associated with tumours in the thalamus 
compared with other regions (4/12 compared to 1/88; 
p = 0.001). Three patients with HGG presented acutely with 
symptoms; two with headache and signs of papilloedema, 
and one with a new cranial nerve palsy and ataxia. Only 
two of the patients with HGG had previous imaging, both 
of which showed lesions involving the thalamus—one of 
the patients had previous debulking of a frontal/thalamic 
lesion, and the histology showed a pilomyxoid astrocytoma 
before transforming to a HGG.
Details of the five patients with high-grade glioma are 
outlined in Table 1.
Survival analysis and outcome
Five of the 100 patients died during follow-up; two from 
progression of a low grade tumour to a high-grade glioma, 
two presented acutely with a high grade tumour in the first 
instance, and one patient developed cerebellar necrosis fol-
lowing radiotherapy. The survival rate from diagnosis was 
95% at 5 years (95% CI 92.6–97.4%). On multivariate Cox 
regression to evaluate predictive factors related to death, 
the diagnosis of high grade glioma had a HR of 99.7 (95% 
Fig. 2  Flow diagram of the requirement for surgery in 100 patients 
with NF1 related glioma (immediate surgery refers to surgery within 
2 months of initial presentation, HGG high grade glioma)
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CI 11.1–898.9, p < 000.1). There was no significant asso-
ciation between age at tumour detection and death.
At last follow-up 29/95 survivors had symptoms related 
to glioma with an EDSS of 2.2 (SD 1.6). Fifty-seven per-
cent (21/37) of patients who had surgery had symptoms at 
follow up compared to 14% of patients who did not require 
surgery (p < 0.0001). Patients who were symptomatic at the 
time of diagnosis had a higher mean EDSS at most recent 
review (1.5) compared to individuals who had a glioma 
diagnosed incidentally (0.5), p = 0.01.
Serial neuroimaging was undertaken in 88 patients. 
The median time between first and most recent imaging 
was 59 months (range 2–453). In 66/88 (75%) the lesion 
on the scan was stable or had improved, and 22/88 (25%) 
showed radiological progression. Lesions in the thalamus 
(p = 0.004) were more likely to undergo radiological pro-
gression, however this was related to the transformation to 
high grade malignancy.
Previous history of OPG was present in 25/100 but was 
not associated with poorer outcome or high-grade tumour.
Discussion
We have shown that tumours in the thalamus are more 
likely to be associated with high-grade tumours in NF1. 
As a result of this finding, heightened surveillance with 
more frequent imaging should be considered in patients 
with NF1 who have thalamic involvement. Individuals 
with tumours in the thalamus, frontal lobes, and cerebel-
lum were more likely to require surgical intervention than 
patients with tumours in other anatomical locations. At the 
current time there are no consensus guidelines, and height-
ened surveillance in this subset of patients may lead to a 
decrease in morbidity and mortality.
Forty-two percent of patients (n = 42) underwent surgi-
cal intervention. Predictors of the requirement for surgical 
intervention included symptoms that necessitated cranial 
imaging, and thalamic, cerebellar and frontal lesions. We 
identified that 64% of patients requiring intervention had 
surgery within 2 months, and 91% of patients who needed 
intervention had surgery within 5 years of tumour detec-
tion. Overall the outcome was very favourable with 95% 
survival at 5 years, and 92% at 10 years. 65% of patients 
were asymptomatic at follow-up. We did not find an asso-
ciation between the age at tumour diagnosis and need for 
surgery and there was not association with death; however 
there was a trend towards significance and this may reflect 
the small size of out cohort.
The majority of tumours biopsied were pilocytic astro-
cytomas, and only five patients (5%) in this cohort devel-
oped a high-grade glioma. Our findings are supported by 
three studies [3, 4, 7] that reported that the majority of 
progressive tumours were not pilocytic astrocytomas but 
rather other types of astrocytoma, that are associated with 
a more aggressive histological subtype. Guillamo and 
colleagues showed that of 19 progressive tumours; only 
nine were pilocytic astrocytomas, with the remaining ten 
tumours comprising two low grade astrocytomas, two ana-
plastic astrocytomas, two glioblastomas, and one dysplastic 
neuroepithelial tumour [7].
Leonard and colleagues reported that over half of 
patients with unusual clinical presentation or radiographic 
features were not classic pilocytic astrocytomas on histo-
logical analysis, and highlighted the value of biopsy in 
those cases [8].
This study is limited by the fact that, histological diag-
nosis was only obtained in the minority of cases (32/100), 
with the remaining diagnoses were suspected radiologi-
cally. Radiological progression (improved/stable/worse) 
was assessed by experienced neuroradiologists, using linear 
measurement and qualitative assessment rather than volu-
metric analysis.
In NF1 individuals brain lesions that have irregular 
enhancement, have marked mass effect, or show restricted 
diffusion are probable gliomas that require judicious clini-
cal and neuro-radiological follow up. There are currently 
no guidelines on the surveillance of NF1 patients once a 
non-optic pathway glioma has been identified. Lack of evi-
dence makes determining a time interval for serial imag-
ing extremely difficult, especially when patient anxiety is 
heightened by an underlying disorder that predisposes to 
tumours. We found that all high-grade gliomas and nearly 
all tumours requiring surgery did so within 5 years of 
tumour detection, and that the majority were symptomatic 
at presentation. Serial imaging should be undertaken for at 
the very least, 5 years from tumour detection.
We also found that tumours located in the thalamus 
were more likely to be associated with high-grade tumours 
(2 cases) and high-grade transformation (2 cases), so that 
location of tumour should direct one toward more frequent 
imaging. Krishnatry and colleagues reviewed LGG in over 
1200 patients and found an association between mortality 
and thalamic lesion, however only 10% of this cohort had 
NF1 and the majority of patients with NF1 had an optic 
pathway glioma, and an excellent outcome [9]. As up to 
85% of children with NF1 have abnormal signal on their 
MRI scans (FASIs), and the thalamus is a common location 
to see these changes [10], it is important to discuss cases 
with an experienced neuroradiologist to ensure that FASI 
don’t have any atypical features that may suggest the pres-
ence of a low grade glioma.
The patients in this series were referred to a national 
neurofibromatosis centre and may represent a more com-
plex case mix, which may not be reflective of the NF1 
population as a whole. However, from analysis of the data 
614 J Neurooncol (2017) 133:609–614
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we found that over half of the gliomas were diagnosed 
when patients were scanned for another reason, and that 
fewer than one-fifth of patients identified in that way ever 
required surgery. These patients also had a better outcome 
in terms of EDSS at most recent review. It is difficult to 
tell if symptoms at follow up in those who had surgical 
interventions are secondary to tumour or to side effects of 
surgery. Our practice is to scan patients with clinical signs 
or symptoms and not to perform baseline neuroimaging, 
which may reveal incidental gliomas.
Under current WHO grading, brain tumours are given 
a Grade of I–IV depending on histological features [11]. 
In future the use of molecular genetic findings will aid in 
determining the course and prognosis of low-grade tumour 
types and also allow allocation of specific, targeted onco-
logical therapy in these patients. One of our patients was 
diagnosed with a cerebellar ganglioglioma and had molec-
ular genetic analysis that revealed a V600E BRAF muta-
tion. The BRAF pathway is a key regulator of the MAPK 
pathway [12], and targeted treatment with a BRAF-MEK 
pathway inhibitor would be a potential therapy. Molecular 
genetic analysis of tumours may aid in decisions regarding 
therapy.
In conclusion, MRI should be undertaken in patients 
with NF1 who have signs and symptoms suggestive of gli-
oma. Once a glioma is diagnosed any new symptoms indi-
cating progression should be investigated promptly. Patient 
education regarding ‘red flag’ symptoms may hasten refer-
ral to neurosurgical services. Heightened surveillance with 
more frequent imaging should be considered in patients 
with thalamic involvement, and also in those with atypical 
histological findings for at least 5 years. Overall the out-
come is very favourable with the majority of patients being 
symptom free at most recent follow-up.
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